Please assess the completion status of the following clinical trial:

Trial Title: SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Provided consent to participate in the study~* Male or female, 12 years of age and older~* Clinical diagnosis of asthma for at least 1 year prior to the randomization~* Clinic PEF of greater than or equal to 50% of predicted normal value~* Subject must be appropriately using one of the treatments for asthma listed in the protocol~* Subject must be able to complete the asthma control questionnaire, daily questions about asthma, and use a DISKUS inhaler~* Subject must have history of at least 1 asthma exacerbation including one of the following in the year prior to randomization:~* requiring treatment with systemic corticosteroids~* an asthma-related hospitalization~Exclusion Criteria:~* History of life threatening asthma defined for this protocol as asthma episode that required intubation and/or was associated with hypercapnea requiring non-invasive ventilatory support~* Concurrent respiratory disease other than asthma~* Current evidence of, or ever been told by a physician that they have chronic bronchitis, emphysema, or chronic obstructive pulmonary disease.~* Exercise induced asthma (as the only asthma-related diagnosis) not requiring daily asthma control medicine~* Presence of a bacterial or viral respiratory infection that is not resolved at randomization~* An asthma exacerbation requiring systemic corticosteriods within 4 weeks of randomization or more than 4 separate exacerbations in the 12 months preceding randomization~* More than 2 hospitalizations for treatment of asthma in the 12 months preceding randomization~* Subject must not meet unstable asthma severity criteria as listed in the protocol~* Potent cytochrome P450 3A4 (CYP3A4) inhibitors within the last 4 weeks (e.g., ritonavir, ketoconazole, itraconzole)~* Pregnancy, breast-feeding or planned pregnancy during the study~* A Child in Care (CiC) is a child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADVAIR 100/50mcg (Type: EXPERIMENTAL): experimental drug
- ADVAIR 250/50mcg (Type: EXPERIMENTAL): experimental drug
- ADVAIR 500/50mcg (Type: EXPERIMENTAL): experimental drug
- FLOVENT 100mcg (Type: ACTIVE_COMPARATOR): active comparator
- FLOVENT 250mcg (Type: ACTIVE_COMPARATOR): active comparator
- FLOVENT 500mcg (Type: ACTIVE_COMPARATOR): active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).